Literature DB >> 22075513

Primary Plasma Cell Leukemia Associated with t(6;14)(p21;q32) and IGH Rearrangement: A Case Study and Review of the Literature.

Sun Young Cho1, Gayoung Lim, Seung Hwan Oh, Hee Joo Lee, Jin-Tae Suh, Juhie Lee, Woo-In Lee, Hong Ghi Lee, Hwi-Joong Yoon, Tae Sung Park.   

Abstract

Because plasma cell leukemia (PCL) is a rare and distinct variant among plasma cell dyscrasias, recent clinical and cytogenetic studies have been performed in different ethnic groups to define the characteristics of these PCL patients. As far as we know, IGH rearrangements involving t(11;14) and (14;16) are significantly more frequent in PCL than in myeloma patients. However, PCL cases associated with t(6;14)(p21;q32) or IGH-CCND3 rearrangement are extremely rare in the literature; only one PCL case with t(6;14) has been documented. A 61-year-old female was admitted due to fatigue, weight loss, and exertional dyspnea. Plasmacytoid cells were counted up to 76% at a peripheral blood film, but bone marrow aspiration failed because of dry-tapping. Flow cytometric analysis showed positive for CD138 and cytoplasmic kappa light chain. Chromosome analysis revealed t(6;14)(p21;q32), which was confirmed by an IGH split-out probe in FISH analysis. Immunofixation electrophoresis also presented monoclonal bands identified as IgG and kappa light chain. Finally, she was diagnosed as primary PCL associated with t(6;14) and IGH rearrangement. Although considerable advances have been made in the understanding of the biology and molecular pathogenesis of PCL, further clinical, laboratory, and genetic studies of PCL associated with such a rare IGH rearrangement would be necessary in the future. To the best of our knowledge, this is the first report of PCL associated with t(6;14) as a sole chromosomal abnormality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075513

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  2 in total

1.  Plasma cell myeloma initially presenting as lung cancer.

Authors:  Sun Young Cho; Jae-Heon Jeong; Woo-In Lee; Juhie Lee; Il Ki Hong; Jin-Tae Suh; Hee Joo Lee; Hwi-Joong Yoon; Tae Sung Park
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

2.  Acquired del(9)(p22.3) in a primary plasma cell leukemia.

Authors:  Walid Al Achkar; Abdulsamad Wafa; Abdulmunim Aljapawe; Moneeb Ak Othman; Eyad Alhourani; Thomas Liehr
Journal:  Mol Cytogenet       Date:  2013-08-28       Impact factor: 2.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.